跳至主要内容
临床试验/NCT00098852
NCT00098852Unknown2 期

A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer

University of California, San Francisco2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2004年10月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
25
试验地点
2
主要终点
Radioiodine uptake and thyroglobulin level at 6 months and 1 year

研究概览

简要总结

RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine.

PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.

详细描述

OBJECTIVES:

Primary

  • Determine complete response in patients with locoregionally extensive or metastatic differentiated thyroid cancer treated with rosiglitazone.

Secondary

  • Compare the long-term response of patients treated with this drug with historical controls.
  • Determine the toxicity profile of this drug in these patients.
  • Determine the presence/persistence of tumor in patients treated with this drug.
  • Determine the quality of life of patients treated with this drug.
  • Determine overall survival of patients treated with this drug.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Radioiodine uptake and thyroglobulin level at 6 months and 1 year

次要结局

  • Side effects of drug at 2 months

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验